Search
Oxymorphone
go.drugbank.com/drugs/DB01192ApprovedVet approvedOn June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.
Perboric acid
go.drugbank.com/drugs/DB13235ApprovedPerboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate or tetrahydrate. … [L1113] By the FDA, sodium perborate is approved as an ointment for the protection of poison ivy dermatitis.[L2764]
Ferrous sulfate anhydrous
go.drugbank.com/drugs/DB13257ApprovedInvestigational[A190804] This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells. … Iron deficiency anemia is a large public health concern worldwide, especially in young children, infants, and women of childbearing age.
Mixtures: Phytofortis + Calcium A-D, Hormodausse Plus Calc Et D TabLeniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigationalLeniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). … The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).
Vanzacaftor
go.drugbank.com/drugs/DB18373ApprovedInvestigational], a CFTR potentiator, for the treatment of patients with responsive CFTR mutations. … [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor
Enmetazobactam
go.drugbank.com/drugs/DB18716ApprovedInvestigationalEnmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor. … [A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.
Vedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigationalVedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative … to its predecessor natalizumab, the first integrin receptor antagonist approved by the FDA.
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigational[A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. … [A261165] However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns.
Relatlimab
go.drugbank.com/drugs/DB14851ApprovedInvestigational[L41300] Opdualag was subsequently approved in the European Union in July 2022[L49996] and in Canada in September 2023.[L50001] … [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval.
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigationalLisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel]. … [A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4.